ADARx prices $446.3 million Nasdaq debut, boosting biotech IPO wave
read at Endpoints ↗DealNeutral
ADARx Pharmaceuticals, a RNA interference focused biotech, announced pricing of its initial public offering at $446.3 million on Nasdaq.
The offering was upsized, reflecting strong investor demand and adding to a recent surge of biotech IPOs.
The debut underscores continued momentum in the biopharma sector’s public market activity.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “ADARx prices $446.3M Nasdaq debut, continuing industry's IPO momentum”
read at Endpoints ↗80 words · retrieved Sep 25
comments(0)
5-min edit window · permanent after that